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Abstract: This article aims to investigate the clinical results at 2 years
after selective laser trabeculoplasty (SLT) for normal tension glaucoma
(NTG).
This prospective cohort study recruited NTG patients taking anti-
glaucoma medication. Subjects were excluded if they had previous
glaucoma surgery/laser or corneal pathologies. All subjects underwent a
1-month washout. A single session of SLT was performed to 3608 of the
trabecular meshwork. Medication was resumed at 1 month to achieve a
targeted 30% intraocular pressure (IOP) reduction from the post-wash-
out/pre-SLT IOP. IOPwasmeasured every 3months andmedication use
was recorded at 3, 6, 12, and 24 months. Subjects with a secondary SLT
or cataract extraction were excluded from IOP and medication analyses.
At 24months, 34 of the initial 45 right eyes were eligible for analyses.
There were significant IOP reductions at all time intervals (except at 1
week) following SLT when compared to the prestudy (without medi-
cation) or pre-SLT (post-washout) IOP (P< 0.0001). Medications were
likewise significantly reduced at all time intervals following SLT
(P< 0.0001). At 24 months, the IOP was 11.5% lower than the prestudy
IOP, 22.0% lower than the pre-SLT IOP, andmedication usewas reduced
by 41.1% (P< 0.0001). Six out of 45 eyes (13.3%) required a secondary
SLT. Absolute success (IOP reduction >20% from pre-SLT, without
medication) was achieved in 11.1% (5/45).
Reductions in IOP and medication use were evident at 2 years
following SLT for the treatment of NTG whereas 11% remained
medication free.
Trial Registrations: The Clinical Trials Register of the University of
Hong Kong HKCTR1847. The European Clinical Trials Database 2014-
003305-15 (August 11, 2014).
(Medicine 94(24):e984)
Abbreviations: ALT = argon laser trabeculoplasty, IOP =
intraocular pressure, NTG = normal tension glaucoma, POAG =
primary open-angle glaucoma, SLT = selective laser trabe-MRCSEd, Jonatha FRCS,
. Lai, MD
INTRODUCTION
N ormal tension glaucoma (NTG) has a high prevalence inAsian countries.1,2 Selective laser trabeculoplasty (SLT) is
safe and as effective as medication in the treatment of primary
open-angle glaucoma (POAG).3–5 More recently, SLT was also
found to be effective for the treatment for NTG, reducing the
intraocular pressure (IOP) anywhere from 12% to 15% for up to
1 year.6–8 The effect of SLT is not permanent and a proportion
of treated patients may continue to require additional medi-
cation, secondary lasers, or even glaucoma filtration procedures
throughout the course of their disease.8,9 The objective of this
study was to investigate the 2-year clinical results of using SLT
in the treatment of NTG.
METHODS
This study adhered to the tenets of the Declaration of
Helsinki. Informed patient consent and approval by the Institu-
tional Review Board of The Hospital Authority of Hong Kong
were obtained prior to study commencement.
The study was registered with the following publicly
accessible registries: the Clinical Trials Register of the Univer-
sity of Hong Kong (trial registration number: HKCTR1847) in
April 2012 and retrospectively registered with the European
Clinical Trials Database (trial registration number: 2014-
003305-15) on August 11, 2014.
The methodology of this study has been previously
described in parts in earlier publications reporting the short-
term clinical results.8,10 This was a prospective cohort study
from July 2012 to July 2014, conducted at a university hospital
in Hong Kong. The study recruited cases of unilateral or
bilateral NTG subjects who were currently on topical antiglau-
coma medications. NTG was defined by open angle on gonio-
scopy, glaucomatous visual field loss on Humphrey visual field
analyzer as per the Hodapp–Parrish–Anderson criteria,11 pro-
gressive thinning of the retinal nerve fiber layer (RNFL) on
optical coherence tomography (OCT), and Goldmann applana-
tion-measured IOP <21 mm Hg on all documented clinical
visits prior to study recruitment. Cases were excluded if they
had received prior surgery or laser for the treatment of glaucoma
or taking any systemic medications that may affect IOP. Patients
were also excluded if there were contraindications for SLT such
as corneal pathologies or scars, not completing the 24-month
follow-up, or if any intraocular surgery or repeated SLT was
performed within 24 months of the first SLT treatment.
The prestudy IOP with antiglaucoma medication and the
number of antiglaucoma medication used were recorded prior to
study enrolment. Fixed combination eye drops were counted as
2 types of antiglaucoma medication. All patients then under-
went a 1-month washout period in which all antiglaucomaontinued. A mean pre-SLT IOP without
lculated after IOP phasing at 9 AM, 1 PM,
al target IOP was calculated as a 30%
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reduction from the pre-SLT IOP, as per the findings from The
Collaborative Normal Tension Glaucoma Study.12
All patients received a single session of SLT using a Q-
switched Nd:YAG laser (Ellex Solo; Ellex Medical Pty. Ltd.,
Adelaide, SA, Australia) with an initial energy of 0.8 mJ. The
power was titrated up or down until bubble formation was just
visible. A single glaucoma specialist (J.W.Y.L.) delivered the SLT
treatment and both eyes were treated in the same laser session for
those with bilateral disease. In all treated eyes, a single drop of
brimonidine tartrate (Alphagan P; Allergan Inc., Waco, TX) was
instilled immediately after SLT. Dexamethasone 0.1% and neo-
mycin 0.5% combination eye drop (Dexoptic-N by Ashford
Laboratories Pvt. Ltd., Dheeraj Heritage, S.V. Road, Santacruz
West, Mumbai, India) was used twice daily for 1 day and was
continued for a few more days only if anterior chamber reaction
was seen on day 1 after SLT. Subjects returned for follow-up on
day 1, 1 week, 1 month, 3 months, 6 months, 9 months, 12 months,
18 months, and 24 months after SLT. At 1 month after SLT, IOP
phasing (9 AM, 1 PM, and 5 PM) was repeated and a mean 1-month
IOP was calculated. IOP phasing was only performed before SLT
and again 1 month after SLT. Antiglaucoma medications were
resumed and titrated based on clinical response to achieve the
preset target IOP for each individual. The order of resuming
antiglaucoma medications was as follow: a-adrenergic agonists
or prostaglandin analogs followed by topical carbonic anhydrase
inhibitors and, lastly, B-blockers. This order was based on the
understanding from the Low-Pressure Glaucoma Treatment
Study that NTG subjects treated with a-adrenergic agonists were
less likely (9.1%) to develop visual field progression than those
using B-blockers (39.2%).13 When multiple medications were
required, fixed combination medications were given to simplify
the drug regimen.
The primary outcome measure included IOP at the follow-
ing time intervals: prestudy (with medication), pre-SLT (post-
washout), 1 day, 1 week, 1 month, 3 months, 6 months, 9
months, 12 months, 18 months, and 24 months after SLT.
Goldmann applanation tonometry was used to measure IOP.
The secondary outcomes included the following: the num-
ber of antiglaucoma medications used prestudy and at 3, 6, 12,
and 24 months after SLT. Absolute success was defined as IOP
reduction 20% from the pre-SLT IOP without any additional
antiglaucoma medication. The baseline and 24-month Snellen
visual acuity, RNFL on OCT, as well as the pattern standard
deviation (PSD) and visual field index (VFI) on Humphrey
visual field were recorded.
Statistics
The D’Agostino and Pearson omnibus normality test was
used to test for normality. Only the right eye was used for
Lee et alstatis
roni
base
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2.
2 |tical analysis. Repeated measures ANOVA with Bonfer-
multiple comparison test was used to calculate the follow-
outcome measures over the study period:ing
1. IOP at prestudy, pre-SLT, and at 1 day, 1 week, 1 month, 3
months, 6 months, 9 months, 12 months, 18 months, and 24
months post-SLT.
2. Number of antiglaucoma eye drops at prestudy and at 1, 3,
6, 12, and 24 months post-SLT.A paired t test was used to compare the following at
line and 24 months:
Snellen visual acuity
RNFL on OCT
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Those with a repeated SLT or phacoemulsification in the
treated eye were excluded from the above statistical analysis on
IOP and medication use as the IOP changes in these subjects
would no longer be solely attributed to the effects of the initial
SLT procedure. These subjects, however, will still be included
in the calculation of the percentage of absolute success and the
survival curve as described further.
A Kaplan–Meier survival curve was used to represent the
‘‘mortality’’ after SLT, which was defined as the need of a repeat
SLT procedure to further lower IOP or medication load. All
means were expressed as mean standard deviation. Statistical
significance was defined as P< 0.05.
RESULTS
In the initially recruited 46 NTG subjects (45 right eyes and
38 left eyes), 1 was deceased, 6 required a secondary SLT
treatment, and 5 had a phacoemulsification with intraocular lens
implantation within the 24-month period. In the remaining 34
subjects that completed the 24-month follow-up, the mean age
was 65.1 12.1 years. There were 18 males and 16 females with
34 right eyes and 28 left eyes. All subjects were ethnic Chinese
with pigmented and open-angle configurations. The mean SLT
shots delivered was 191.0 27.3 at a mean energy of
1.0 0.08mJ.
The 34 right eyes were used for the statistical analyses on
IOP and medication use. Whether using the prestudy IOP (with
medication) or the pre-SLT IOP (post-washout, without medi-
cation) as the basis of comparison, there were significant IOP
reductions at all time intervals following SLT (all P< 0.0001),
except at 1 week, where there was no significant difference with
the prestudy IOP or pre-SLT IOP (P> 0.05) (Table 1, Figure 1).
At 24 months, the IOP was 11.5% lower than the prestudy
IOP (P< 0.0001) and 22.0% lower than the pre-SLT IOP
(P< 0.0001). The number of antiglaucoma medications was
also significantly reduced at all time intervals following SLT
when compared to the prestudy level (all P< 0.0001). At 24
months, medication requirement was reduced by 41.1% com-
pared to the prestudy level (P< 0.0001) (Table 2, Figure 2).
During the 24-month period following SLT, 6 out of the
initial 45 right eyes (13.3%) required a secondary SLT pro-
cedure at a mean of 17.8 6.7 months after the initial laser.
Absolute success was achieved in 11.1% (5/45) at 24 months
following SLT (Figure 3).
In the SLT treated eyes, there was no significant progress-
ive thinning in the RNFL (prestudy¼ 72.0 14.0mm, 24
months¼ 70.5 13.1mm, P¼ 0.2). Similarly, the PSD (pre-
study¼ 6.7 3.6 dB, 24 months¼ 7.4 4.2 dB, P¼ 0.2) and
VFI (prestudy¼ 74.9 22.7%, 24 months¼ 75.9 20.4 dB,
P¼ 0.6) on the Humphrey visual field were statistically similar
before SLT and at 24 months after SLT. The visual acuity also
remained unchanged prestudy versus 24 months (base-
line¼ 0.6 0.2, 24 months¼ 0.7 0.2, P¼ 0.2).
DISCUSSION
Previously, the use of argon laser trabeculoplasty (ALT) in
resulted in IOP reductions lasting up to 21.6 months, but
scarring induced by ALT limited its repeatability when the
r effect worn off.14 In earlier studies involving the use of
opyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 1. IOP Before and After SLT for NTG
Mean IOP Reduction From Pre-
study Level
Reduction From PreSLT
Level, %
mm Hg SD % P Value % P Value
Prestudy (with medication) 14.3 3.6 — — — —
Pre-SLT (without medication) 16.2 2.3 — — — —
Day 1 post-SLT 11.2 2.5 21.8 <0.0001 31.0 <0.0001
1 wk post-SLT 14.9 3.3 4.6 >0.05 7.8 >0.05
1 mo post-SLT 12.3 2.1 14.0 <0.0001 24.2 <0.0001
3 mo post-SLT 11.2 2.1 21.4 <0.0001 30.7 <0.0001
6 mo post-SLT 11.2 1.7 21.2 <0.0001 30.5 <0.0001
9 mo post-SLT 11.6 2.1 18.9 <0.0001 28.5 <0.0001
12 mo post-SLT 12.0 2.1 15.6 <0.0001 25.6 <0.0001
18 mo post-SLT 12.7 2.1 10.7 <0.0001 21.2 <0.0001
24 mo post-SLT 12.6 2.7 11.5 <0.0001 22.0 <0.0001
tand
Medicine  Volume 94, Number 24, June 2015 SLT for NTG at 2 YearsSLT in the treatment of a mixed population of NTG and POAG
subjects, the IOP reduction ranged from 14% to 16.5% at
1 year.6,15 More recently, in a prospective study involving just
NTGsubjects, SLTwas effective in lowering the IOPby 20%and
15% at 6 months and 1 year, respectively.8,10 Similarly, Nitta
et al16 used SLT as the initial treatment in 42 NTG subjects and
reported IOP reductions of 16.5% at 1 year and 14.6% at 2 years,
which was in agreement with our finding of a 12% IOP reduction
at 2 years.
The absolute success of SLT in our NTG population tapered
off from 61%, at 6months, to 22% at 1 year, to 11% at 2 years.8,10
At 1 year, 2 (4.3%) of the treated eyes required a secondary SLT.8
By2 years, 6 (13.3%) eyes required a secondary SLTalthough the
mean IOP reduction for the entire study population maintained at
22% lower than the pre-SLT IOP level while using 0.9 0.9
medications at 2 years.
To the best of our knowledge, this is one of the largest and
IOP¼ intraocular pressure, NTG¼ normal tension glaucoma, SD¼ s
Statistically significant.longest longitudinal studies reporting the effects of SLT in a
homogenous NTG study population. Some of the limitations of
our original study design have been previously described in
FIGURE 1. Changes in IOP before and after SLT for NTG, wherein
whiskers represent the 2.5 to 97.5th percentile. IOP¼ intraocular
pressure, NTG¼normal tension glaucoma, SLT¼selective laser
trabeculoplasty.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.earlier publications.8,10 One of the most important limitations
of this article is lack of a control group. In future studies, a
randomized control trial composing of NTG patients continuing
medical treatment would provide more robust results. In particu-
lar, relevance to this 2-year study, it should be pointed out that not
all subjects were able to achieve the initial targeted 30% IOP
reduction as per the Collaborative Normal Tension Glaucoma
study12 as in a realistic clinical environment, patient’swillingness
to endure additional medication or secondary laser procedures
were governed by individual goals, tolerances, and expectations
to treatment. AsNTG is asymptomatic with ‘‘normal pressures,’’
some patients were reluctant to receive additional medication or
undergo additional laser in order to top up the few outstanding
percentages in IOP reduction for statistical completeness. How-
ever, on a whole, the study population already enjoyed a mean
IOP reduction of 22% from the pre-SLT level. Previous studies
have demonstrated that SLT dampens the intervisit IOP variation
and the IOP-related amplitude on 24-hour recordings, whichmay
be related toNTGprogression but analysis of IOP fluctuationwas
beyond the scope of this study.7,17 From the literature, while
pretreatment IOP, number of preexistingmedication, and the total
ard deviation, SLT¼ selective laser trabeculoplasty.SLT energy delivered seemed to influence the success of SLT,
there is no effective formula to date that can predict the sustain-
ability of SLT for an individual prior to laser.18–21 Future studies
TABLE 2. Medications Before and After SLT for NTG
Mean
Number of
Medications
Reduction From
Prestudy
Level, %
n SD % P Value
Prestudy 1.5 0.8 —
3 mo post-SLT 0.9 0.9 40.0 <0.0001
6 mo post-SLT 1.0 1.0 55.6 <0.0001
12 mo post-SLT 1.0 0.8 33.3 <0.0001
24 mo post-SLT 0.9 0.9 40.0 <0.0001
n¼ number, NTG¼ normal tension glaucoma, SD¼ standard devi-
ation, SLT¼ selective laser trabeculoplasty.
Statistically significant.
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FIGURE 2. Changes in the number of antiglaucoma medications
before and after SLT for NTG, wherein the boxes represent the
minimum/maximum and the center line represents the mean.
NTG¼normal tension glaucoma, SLT¼selective laser trabeculo-
plasty.
Lee et alinvestigating the parameters that influence or predict laser sus-
tainabilitywould be of great clinical relevance. The findings from
this study are only applicable to NTG subjects previously receiv-
ing antiglaucoma medications with a 1-month washout period
and may not generalizable to other populations.
CONCLUSION
At 2 years after a single session of SLT in the treatment of
NTG, treated eyes benefited from a 12% IOP reduction with
41% fewer medication, whereas 11% were medication free.
ACKNOWLEDGMENTS
The authors would like to thankMan Yee Lee and her team
of nursing and clerical staff at Queen Mary Hospital for con-
tributing their time and energy to clinical research.
REFERENCES
FIGURE 3. Kaplan–Meier survival curve following SLT, wherein
mortality¼need of a secondary SLT. SLT¼selective laser trabecu-
loplasty.Glaucoma Society. The prevalence of primary open-angle glaucoma
in Japanese: the Tajimi Study. Ophthalmology. 2004;111:1641–1648.
4 | www.md-journal.com2. Kim CS, Seong GJ, Lee NH, et al., Namil Study Group, Korean
Glaucoma Society. Prevalence of primary open-angle glaucoma in central
South Korea the Namil study. Ophthalmology. 2011;118:1024–1030.
3. Wong MO, Lee JW, Choy BN, et al. Systematic review and meta-
analysis on the efficacy of selective laser trabeculoplasty in open-
angle glaucoma. Surv Ophthalmol. 2015;60:36–50.
4. Lee JW, Chan JC, Chang RT, et al. Corneal changes after a single
session of selective laser trabeculoplasty for open-angle glaucoma.
Eye (Lond). 2014;28:47–52.
5. Lee JW, Chan CW, Wong MO, et al. A randomized control trial to
evaluate the effect of adjuvant selective laser trabeculoplasty versus
medication alone in primary open-angle glaucoma: preliminary
results. Clin Ophthalmol. 2014;8:1987–1992.
6. Best UP, Domack H, Schmidt V. Long-term results after selective
laser trabeculoplasty—a clinical study on 269 eyes. Klin Monbl
Augenheilkd. 2005;222:326–331.
7. El Mallah MK, Walsh MM, Stinnett SS, et al. Selective laser
trabeculoplasty reduces mean IOP and IOP variation in normal
tension glaucoma patients. Clin Ophthalmol. 2010;4:889–893.
8. Lee JW, Ho WL, Chan JC, et al. Efficacy of selective laser
trabeculoplasty for normal tension glaucoma: 1 year results. BMC
Ophthalmol. 2015;15:1.
9. Weinand FS, Althen F. Long-term clinical results of selective laser
trabeculoplasty in the treatment of primary open angle glaucoma.
Eur J Ophthalmol. 2006;16:100–104.
10. Lee JW, Gangwani RA, Chan JC, et al. Prospective study on the
efficacy of treating normal tension glaucoma with a single session of
selective laser trabeculoplasty. J Glaucoma. 2015;24:77–80.
11. Hodapp E, Parrish RK, Anderson DR II. Clinical decisions in
glaucoma. St Louis: The CV Mosby Co; 1993:52–61.
12. Collaborative Normal-Tension Glaucoma Study Group. Comparison
of glaucomatous progression between untreated patients with nor-
mal-tension glaucoma and patients with therapeutically reduced
intraocular pressures. Am J Ophthalmol. 1998;126:487–497.
13. Krupin T, Liebmann JM, Greenfield DS, et al. A randomized trial of
brimonidine versus timolol in preserving visual function: results
from the Low-Pressure Glaucoma Treatment Study. Am J Ophthal-
mol. 2011;151:671–681.
14. Schwartz AL, Perman KI, Whitten M. Argon laser trabeculoplasty in
progressive low-tension glaucoma. Ann Ophthalmol. 1984;16:560–5626.
15. Hirn C, Zweifel SA, Toteberg-Harms M, et al. Effectiveness of
selective laser trabeculoplasty in patients with insufficient control of
intraocular pressure despite maximum tolerated medical therapy.
Ophthalmologe. 2012;109:683–690.
16. Nitta K, Sugiyama K, Mawatari Y, et al. Results of selective laser
trabeculoplasty (SLT) as initial treatment for normal tension
glaucoma. Nihon Ganka Gakkai Zasshi. 2013;117:335–343.
17. Lee JW, Fu L, Chan JC, et al. Twenty-four-hour intraocular pressure
related changes following adjuvant selective laser trabeculoplasty for
normal tension glaucoma. Medicine (Baltimore). 2014;93:e238.
18. Lee JW, Liu CC, Chan J, et al. Predictors of success in selective
laser trabeculoplasty for primary open angle glaucoma in Chinese.
Clin Ophthalmol. 2014;8:1787–1791.
19. Lee JW, Liu CC, Chan JC, et al. Predictors of success in selective
laser trabeculoplasty for normal tension glaucoma. Medicine (Balti-
more). 2014;93:e236.
20. Lee JW, Liu CC, Chan JC, et al. Predictors of success in selective
laser trabeculoplasty for chinese open-angle glaucoma. J Glaucoma.
2014;23:321–325.
Medicine  Volume 94, Number 24, June 201521. Lee JW, Wong MO, Liu CC, et al. Optimal selective laser1. Iwase A, Suzuki Y, Araie M, et al., Tajimi Study Group Japantrabeculoplasty energy for maximal intraocular pressure reduction in
open-angle glaucoma. J Glaucoma. 2015;24:e128–e131.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
